ArticleScientific reports2014
Amyloid-beta neuroprotection mediated by a targeted antioxidant.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Anti-Amyloid Aggregation Effects of Gobaishi (Molecules (Basel, Switzerland) · 2025Article
- The Protective Effects of Policosanol on Learning and Memory Impairments in a Male Rat Model of Alzheimer's Disease.Molecular neurobiology · 2023Article
- Policosanol protects against Alzheimer's disease-associated spatial cognitive decline in male rats: possible involved mechanisms.Psychopharmacology · 2023Article
- Systemic Inflammation Predicts Alzheimer Pathology in Community Samples without Dementia.Biomedicines · 2022Article
- Brain Targeting and Toxicological Assessment of the Extracellular Vesicle-Packaged Antioxidant Catalase-SKL Following Intranasal Administration in Mice.Neurotoxicity research · 2021Article
- Prodromal Alzheimer's Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimer's Pathology.Frontiers in neuroscience · 2020Article
- Assessing the therapeutic potential of Graptopetalum paraguayense on Alzheimer's disease using patient iPSC-derived neurons.Scientific reports · 2019Article
- Autophagy induction and PDGFR-β knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection.Scientific reports · 2019Article
- Genetic ablation of tau improves mitochondrial function and cognitive abilities in the hippocampus.Redox biology · 2018Article
- Detection of Amyloid Beta (Aβ) Oligomeric Composition Using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS).Journal of the American Society for Mass Spectrometry · 2018Article
- Peroxisomal Dysfunction in Age-Related Diseases.Trends in endocrinology and metabolism: TEM · 2017Review
- Targeted Antioxidant, Catalase-SKL, Reduces Beta-Amyloid Toxicity in the Rat Brain.Brain pathology (Zurich, Switzerland) · 2017Article
- Development of an in-vivo active reversible butyrylcholinesterase inhibitor.Scientific reports · 2016Article
- Astaxanthin Protects Primary Hippocampal Neurons against Noxious Effects of Aβ-Oligomers.Neural plasticity · 2016Article
- Neural Progenitor Cells Derived from Human Embryonic Stem Cells as an Origin of Dopaminergic Neurons.Stem cells international · 2015Article
- Aβ Clearance, "hub" of Multiple Deficiencies Leading to Alzheimer Disease.Frontiers in aging neuroscience · 2015Review
- Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration.Frontiers in neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Amyloid-beta (Aβ)-induced neurotoxicity is a major contributor to the pathologies associated with Alzheimer's disease (AD). The formation of reactive oxygen species (ROS), an early response induced by the peptide and oligomeric derivatives of Aβ, plays a significant role in effecting cellular pathogenesis. Here we employ particularly toxic forms of Aβ with cultured primary cortical/hippocampal neurons to elicit ROS and drive cellular dysfunction. To prevent and even reverse such effects, we utilized a cell-penetrating, peroxisome-targeted, protein biologic--called CAT-SKL. We show the recombinant enzyme enters neurons, reverses Aβ-induced oxidative stress, and increases cell viability. Dramatic restorative effects on damaged neuronal processes were also observed. In addition, we used DNA microarrays to determine Aβ's effects on gene expression in neurons, as well as the ability of CAT-SKL to modify such Aβ-induced expression profiles. Our results suggest that CAT-SKL, a targeted antioxidant, may represent a new therapeutic approach for treatment of disorders, like Alzheimer's disease, that are driven through oxidative stress. Preclinical testing is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.